Relief of YY1 transcriptional repression by adenovirus E1A is mediated by E1A-associated protein p300

Jeng-Shin Lee, Katherine M. Galvin, Raymond H. See, Richard Eckner, David Livingston, Elizabeth Moran, and Yang Shi

Department of Pathology, Committee on Virology, Harvard Medical School, Boston, Massachusetts 02115 USA; Division of Cellular and Molecular Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115 USA; The Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140 USA

YY1 represses transcription when bound upstream of transcriptional initiation sites. This repression can be relieved by adenovirus E1A. Here, we present genetic evidence that the ability of E1A to relieve YY1 repression was impaired by mutations that affect EIA binding to its associated protein p300. This suggests that E1A may modulate the repressor activity of YY1 by binding to p300, which may be physically complexed with YY1. A YY1/p300 protein complex in vivo was demonstrated by several independent approaches, and the YY1-interacting domain was mapped to the carboxy-terminal region of p300, distinct from the E1A-binding site. Unlike E2F/RB, the YY1/p300 complex is not disrupted by E1A. Functional studies using recombinant p300 demonstrated unequivocally that p300 is capable of mediating E1A-induced transcriptional activation through YY1. Taken together, these results reveal, for the first time, a YY1/p300 complex that is targeted by EIA and demonstrate a function for p300 in mediating interactions between YY1 and E1A. Our data thus identify YY1 as a partner protein for p300 and uncover a molecular mechanism for the relief of YY1-mediated repression by E1A.

[Key Words: Transcriptional repression; adenovirus E1A; YY1; p300; cofactor]

Received February 16, 1995; revised version accepted April 4, 1995.

Adenovirus E1A proteins are the first viral polypeptides synthesized after adenovirus infection (Lewis and Mathews 1980; Nevins 1981). The predominant forms of E1A proteins are encoded by the 12S and the 13S E1A transcripts derived from differential splicing (Berk and Sharp 1978). Discrete regions in E1A that are highly conserved among different adenovirus serotypes have been identified as functionally important for the diverse biological activities of E1A (for review, see Shenk and Flint 1991). These functional domains are designated as conserved regions 1, 2, and 3 [CR1, CR2, CR3]. CR1 and CR2 are common to both the 12S and the 13S E1A, whereas CR3 is unique to the 13S E1A [Kimelman et al. 1985]. The E1A proteins are required for transcriptional activation of other adenoviral genes and are thus essential for the completion of the lytic cycle of the virus (Berk et al. 1979; Jones and Shenk 1979; Lewis and Mathews 1980; Nevins 1981). E1A proteins have also been shown to activate other viral and cellular genes. Although the major transcriptional activation activity has been attributed to CR3 of the 13S E1A, 12S E1A can also activate transcription of a certain subset of promoters [Bagchi et al. 1990; Morris and Mathews 1991].

The mechanisms by which E1A activates transcription remain to be fully elucidated. However, a consensus is emerging that E1A may regulate transcription of its target genes via a mechanism involving protein–protein interactions. E1A has been shown to interact physically with the general transcription factor TATA-binding protein [TBP; Horikoshi et al. 1991; Lee et al. 1991] and with several DNA-binding transcription factors [Liu and Green 1990, 1994]. In some instances, the functional interplay between E1A and transcription factors is mediated by E1A-associated proteins (for review, see Nevins 1992).

One of the targets of E1A is the transcription factor YY1 (Yin Yang 1) [Shi et al. 1991] [NF-E1, Park and Atchison 1991; Hariharan et al. 1991; UCRBP, Flanagan et al. 1992]. YY1 is a zinc finger-containing transcription factor that is a member of the human GLI–Krüppel family of proteins [Ruppert et al. 1988]. YY1 represses or activates transcription, depending on the promoter context (for review, see Shrivastava and Calame 1994). Both repression and activation domains have been identified within YY1, which provides a structural basis for its dual functionality [Lee et al. 1994; Lee et al. 1995]. A large number of cellular and viral genes have been shown to be
negatively regulated by YY1, including genes that are important in differentiation [for review, see Shrivastava and Calame 1994]. Examples of genes positively regulated by YY1 include c-myc [Riggs et al. 1993] and certain ribosomal protein genes [Haribaran et al. 1991]. YY1-binding sites were initially identified in the adenovirus-associated virus P5 promoter whose activity was repressed by YY1 [Chang et al. 1989]. This repression can be relieved by adenovirus E1A, and further activation of P5 promoter transcription occurs [Chang et al. 1989; Shi et al. 1991]. These observations were recapitulated by GAL4 fusion protein-based assays in which GAL4–YY1-mediated transcriptional repression was shown to be relieved by E1A [Shi et al. 1991]. However, the mechanisms underlying the ability of E1A to relieve YY1 repression were not clear. In this report we have analyzed the ability of E1A proteins carrying mutations in the functional domains to relieve YY1 repression. Our results have demonstrated clearly that relief of YY1 repression by E1A is dependent on the ability of E1A to bind its associated protein p300 (Whyte et al. 1989; Wang et al. 1993). p300 was originally identified in a coimmunoprecipitation assay as a cellular protein that interacts with E1A [Yee and Branton 1985, Harlow et al. 1986]. It is related to the coactivator CREB-binding protein (CBP) that binds activated CREB transcription factor [Chrivia et al. 1993; Arany et al. 1994; Arias et al. 1994; Eckner et al. 1994; Kwok et al. 1994] and is likely involved in the regulation of cell growth and differentiation [Jelmsa et al. 1989; Wang et al. 1993; Slack et al. 1995]. However, the partner proteins for p300 and its precise mode of functions are unknown.

The above genetic study of the functional domains of E1A involved in relieving YY1 repression suggested the existence of YY1/p300 complexes in vivo. Using biochemical and immunological assays, we demonstrated the presence of a YY1/p300 complex in vivo. In vitro, YY1 and p300 can directly interact with each other. Significantly, we showed that overexpression of p300 activates YY1-mediated transcription in the presence of E1A, whereas a mutant p300 unable to interact with E1A failed to do so. This reinforces the notion that p300 is an important cofactor that connects E1A to DNA-bound YY1. Glutathione S-transferase (GST) affinity chromatography and coimmunoprecipitation assays indicated that YY1 and E1A both bind to the carboxy-terminal region of p300, but their binding sites are distinct. These data suggested that YY1 and E1A may bind to the same p300 molecule simultaneously. We investigated the status of the YY1/p300 complex in adenovirus-infected HeLa cells and found that the level of the complex was comparable to that in uninfected cells. This is consistent with the possibility that E1A may bind YY1/p300 to form a tripartite complex, in contrast to the E2F/RB complex, which has been shown to be dissociated by E1A.

In summary, our results have uncovered for the first time a molecular mechanism for the relief of YY1-mediated repression by E1A. At the same time, we have identified YY1 as a partner for p300 and a function for p300 as a cofactor that bridges E1A to YY1.

### Results

#### Specific functional interactions between YY1 and adenovirus E1A

The functional interactions between YY1 and adenovirus E1A can be recapitulated by GAL4 fusion protein-based assays [Shi et al. 1991]. As shown in Figure 1, GAL4–YY1 repressed the CAT activity in a dose-responsive manner [cf. lanes 2 and 3 with lane 1]. E1A, but not its frameshift mutant, relieved YY1 repression [Fig. 1, cf. lanes 4–7 with lane 1]. To determine the specificity of this E1A effect, another zinc finger-containing transcriptional factor WT1 [Wilms' tumor 1] was examined [Call et al. 1990, Madden et al. 1991]. GAL4–WT1 effectively repressed the activity of the GAL4–thymidine kinase (TK) promoter [Fig. 1, cf. lanes 8 and 9 with lane 1] as reported [Madden et al. 1991]. However, the repressor function of GAL4–WT1 was unaffected by E1A [Fig. 1, cf. lanes 10 and 11 with lane 9]. Taken together, these data indicate a specific functional interaction between YY1 and E1A.

#### The p300-binding domain of E1A is necessary for E1A to relieve YY1 repression

To understand the mechanisms underlying the ability of E1A to relieve transcriptional repression by YY1, we car-

---

**Figure 1.** The effect of adenovirus E1A on the repressor activity of YY1 is specific. pGAL4–YY1 or pGAL4–WT1 containing the entire coding region of YY1 or WT1 cDNAs was transfected into HeLa cells together with the reporter plasmid pGAL4–TK-CAT in the presence or absence of a plasmid encoding the 13S E1A protein or an E1A frameshift mutant plasmid [for detailed description of all the constructs, see Materials and methods]. The amount of transfected plasmid DNAs and the combination of plasmids used in each transfection are indicated. The extent of acetylation in various reactions was determined relative to that for pGAL4–TKCAT transfected alone. The relative CAT activity reported as 1 represents an average CAT conversion of 30%. CAT assay results (average of three experiments) are shown at the bottom.
Lee et al. carried out experiments to identify domains of E1A that were involved in this process. E1A mutants with gross deletions that disrupted the functional domains (CR1, CR2, and the amino-terminal domain) were analyzed. A representative chloramphenicol acetyltransferase (CAT) assay autoradiograph is shown in Figure 2A, and the results are summarized in Figure 2C. As shown in Figure 2A, wild-type E1A, but not the frameshift mutant of E1A, relieved repression (Fig. 2A, lanes 2, 3, 9). Deletion of the amino-terminal 36 amino acids of the 12S or the 13S E1A completely abolished their ability to alter the repressor activity of YY1 (Fig. 2A, cf. lanes 4 and 6 with lanes 3 and 5). Similarly, deletion of CR1 virtually eliminated the effect of E1A on YY1 (Fig. 2A, lane 7). In contrast, deletion of CR2 essentially had no effect as it retained 74% of the wild-type 12S E1A activity (Fig. 2A, lane 8). These results indicated the importance of the amino-terminal region as well as CR1 in relieving repression mediated by YY1. The amino-terminal domain and CR1 of E1A are involved in the binding of cellular proteins p300 and retinoblastoma protein (RB) family members [Whyte et al. 1989; Wang et al. 1993]. As shown below, it is likely that RB and its related proteins are not involved in this biochemical pathway leading to relief of YY1-mediated repression by E1A in HeLa cells.

Because analysis of the E1A deletion mutants suggested the importance of the amino-terminal region of E1A, mutants with single amino acid substitutions in this region were examined. RG2, HN3, and LS20 all harbor single amino acid substitutions at positions 2, 3, and 20, respectively. These mutants exhibit impaired abilities to bind p300 but bind the RB family of proteins like wild-type E1A (Whyte et al. 1989; Wang et al. 1993). Functionally, all three mutants had greatly reduced abilities to relieve YY1-mediated repression (Fig. 2B, lanes 4–6). In contrast, single amino acid substitutions within CR1 and CR2 (pm47/124) that impaired binding of E1A to the RB family of proteins had virtually no effect on the ability of the mutant to relieve repression by YY1 (Fig. 2B, lane 7). The expression of the mutant proteins in the same lysates used for CAT assays was examined by Western blotting using α-E1A antibodies [Whyte et al.

Figure 2. The amino-terminal region of E1A is necessary to relieve YY1-mediated transcriptional repression. (A, B) Plasmid DNAs were transfected into HeLa cells for analysis of the E1A domains required for relief of YY1-mediated repression. Representative CAT assay autoradiographs are shown. The E1A mutants used in each transfection reaction are indicated at the top. The results are summarized in C. In addition, schematic diagrams of wild-type and various deletion mutants of E1A used in the experiments are shown. Locations of CR1, CR2, and CR3 within E1A are indicated. The abilities of various E1A proteins to bind pRB, p107, and p300 are indicated (+ or −). Weak binding is indicated (+/−) (data taken from Whyte et al. 1989; Wang et al. 1993). Quantitative analyses of the CAT assay results from A and B are presented with mean ± S.D. from three independent transfections. [ND] Not determined.
E1A proteins as wild-type 13S in the transfected cells binding) in 13S E1A virtually had no effect on activation E1A-carrying deletion or point mutations in the amino-terminal region all manifested an impaired ability to activate YY1-mediated transcription (Fig. 3, lanes 3-6). In contrast, a point mutant at amino acid 47 (abolishes RB and/or its related proteins) did not activate YY1 (Fig. 3, lane 7). Western blot analysis showed that all mutants expressed comparable levels of E1A proteins as wild-type 13S in the transfected cells.

As shown in Figure 3, the 13S E1A, but not the frameshift mutant, activated GAL4-E1BCAT in the presence of GAL4-YY1 (Fig. 3, lanes 1,2), consistent with the data obtained using the GAL4-TKCAT reporter plasmid described above. The activation is dependent on YY1 because E1A alone has no effects on GAL4-E1BCAT (Liu and Green 1994; data not shown). Interestingly, 13S E1A-carrying deletion or point mutations in the amino-terminal region all manifested an impaired ability to activate YY1-mediated transcription (Fig. 3, lanes 3-6). In contrast, a point mutant at amino acid 47 (abolishes RB binding) in 13S E1A virtually had no effect on activation through YY1 (Fig. 3, lane 7). Western blot analysis showed that all mutants expressed comparable levels of E1A proteins as wild-type 13S in the transfected cells.

Identification of the p300-binding domain of E1A as the critical element for relieving YY1-mediated repression suggested the involvement of p300 in this process. By analogy to the E2F paradigm in which E1A activates E2F by binding to RB that is physically complexed with E2F (Nevins 1991, 1992, Dyson and Harlow 1992), one may hypothesize that E1A modulates the activity of YY1 by binding to p300, which may be complexed with YY1. Immunoprecipitation/Western blotting experiments were carried to determine whether YY1 and p300 interact physically in vivo. HeLa whole cell extracts were incubated with a polyclonal antibody against YY1 or with rabbit preimmune antibodies as a control. The immunoprecipitates were separated by SDS-PAGE, blotted, and probed with α-p300 monoclonal antibodies (Eckner et al. 1994). To facilitate localization of p300 on the blot, 293 whole cell extracts were incubated with α-E1A antibody M73 (Whyte et al. 1989). As shown in Figure 4A, p300 is visible in the immunocomplex brought down by the α-YY1 antibody (lane 2, HeLa cells) as well as by the α-E1A antibody M73 (lane 4, 293 cells) but not in the complex brought down by the rabbit or mouse preimmune antibodies (Fig. 4A, lanes 1,3). To ensure that the presence of the p300 protein in the YY1 immunocomplex is specific, the same blot was reprobed with an antibody against the E1A-associated protein p107 (Dyson et al. 1993). As shown in Figure 4B, p107 was brought down by M73 from 293 cells (lane 4), as expected, but not by α-YY1 antibodies from HeLa cells (lane 2). These observations suggest that YY1 interacts physically with p300 but not with RB family proteins. This is consistent with the results from functional studies described above suggesting that the RB family of proteins were not involved in relief of YY1-mediated repression by E1A in HeLa cells.

The reciprocal immunoprecipitation/Western experiment was also performed using α-p300 monoclonal antibodies to coimmunoprecipitate YY1. As shown in Figure 4C, YY1 is detected in the immunocomplex brought down by α-p300 antibodies (lane 3) but not by normal mouse serum (lane 2). The prominent bands in lanes 2 and 3 represent immunoglobulin proteins from the immunoprecipitation reactions that are recognized by goat α-rabbit antibodies in the subsequent Western assay. To ascertain the specificity of the immunoprecipitation/Western reactions, competition experiments were performed using bacterially purified GST or GST–YY1 proteins. As shown in Figure 4C (right), the level of endogenous YY1 coprecipitated by α-p300 antibodies was reduced in the presence of GST–YY1, accompanied by the appearance of GST–YY1 (Fig. 4C, cf. lanes 5 and 6). This experiment further confirmed that the band detected by affinity-purified α-YY1 polyclonal antibodies (Fig. 4C, lane 3) is most likely YY1. The interaction be-
Lee et al.

Figure 4. Physical interactions of YY1 and p300. Top panel (A) p300 immunoblot analysis of immunoprecipitates from HeLa or 293 cells obtained with rabbit preimmune serum [lane 1], α YY1 polyclonal antibody [lane 2], normal mouse serum [lane 3], or α-E1A monoclonal antibody M73 [lane 4]. The position of the p300 is indicated by an arrow at right. Molecular mass markers are shown at left. Asterisks (*) indicate nonspecific bands present in both preimmune and immune serum. (B) p107 immunoblot analysis of the same immunoprecipitates from A. (C, left) YY1 immunoblot analysis of immunoprecipitates from HeLa cells obtained with normal mouse preimmune serum (lane 2) and α-p300 monoclonal antibodies (lane 3). The position of YY1 is shown using HeLa nuclear extracts (lane 4) and is indicated by an arrow at right. Molecular mass markers are shown at left. (C, right) YY1 immunoblot analysis of α-p300 immunoprecipitates from HeLa cell lysates preincubated with purified GST [lane 5] or GST–YY1 [lane 6]. The position of YY1 is shown using the input HeLa cell lysate [lane 7] and is indicated by an arrow at right. The position of GST–YY1 is also indicated. (D) Interaction of endogenous YY1 with various GST–p300 deletion mutants. HeLa nuclear extracts were incubated with GST-p300 mutants consisting of the amino-terminal, carboxy-terminal, and central portions of the protein [lanes 3–5] or with GST moiety alone [lane 2]. The bound YY1 protein was visualized by immunoblot analysis using α-YY1 antibodies. YY1 is indicated by an arrow at right. Molecular mass markers are shown at left. (Lane 1) Input HeLa nuclear extract. (E) Two-hybrid assays of YY1/ p300 interactions in vivo. Different combinations of expression vectors were cotransfected into HeLa cells with the reporter GAL4–E1BCAT as indicated (+ or −).

Tweegeen YY1 and p300 was also demonstrated using a GST affinity matrix-based assay (Kaelin et al. 1991). HeLa extracts were incubated with GST–p300 affinity beads, and the bound YY1 proteins were visualized by Western blot analysis using α-YY1 monoclonal antibodies. As shown in Figure 4D, YY1 was captured by the carboxy-terminal (amino acids 1572–2370) but not by the amino-terminal (amino acids 1–596) or the central portions of the p300 protein (amino acids 744–1571), suggesting that the carboxy-terminal region contains an element important for YY1 binding (Fig. 4D).

To ascertain that YY1 and p300 interact physically in vivo, two-hybrid assays were carried out in HeLa cells (Fields and Song 1989; Lillie and Green 1989). As shown in Figure 4E, the carboxy-terminal region of p300 [amino acids 871–2377], when fused to herpes simplex virus [HSV] VP16 activation domain [Cp300/VP16], activated GAL4–E1BCAT in a dose-responsive manner, dependent on the presence of the GAL4–YY1 proteins [lanes 3,4]. This activation requires binding of GAL4–YY1 to the promoter, because the same target gene lacking the GAL4 sites was not responsive to Cp300/VP16 (data not shown). The same Cp300/VP16 fusion protein did not affect the GAL4 DNA-binding domain alone [lanes
p300 mediates YY1/EIA functional interactions

15,16) or GAL4–WT1 (lanes 12,13)-mediated transcription. Furthermore, the N terminal region of p300 (amino acids 1–1275) fused to the VP16 activation domain [Np300/VP16] did not support GAL4–YY1-mediated activation of the GAL4–E1BCAT reporter (lanes 5,6). Taken together, the results suggest in vivo YY1/p300 interaction, and the importance of the carboxy-terminal region of p300 in this interaction. These findings are consistent with those obtained in the immunoprecipitation/Western and the GST affinity matrix assays described earlier.

It is possible that the in vivo YY1/p300 interaction may be mediated by other proteins. To determine whether YY1 and p300 directly interact, bacterially purified His-tagged YY1 (Shi et al. 1991) was incubated with purified GST–p300 (amino acids 1572–2370) attached to glutathione–agarose beads. As shown in Figure 5, substantial amounts of His–YY1 were captured by the GST–p300 affinity column (lane 4) but not by GST alone (lane 3), suggesting that YY1 and p300 can interact directly in vitro.

p300 activates YY1-mediated transcription in the presence of E1A

The genetic study demonstrating the importance of p300 in the relief of YY1 repression by E1A, together with the identification of the YY1/p300 complex in vivo, suggested strongly that p300 is the mediator between YY1 and E1A. To demonstrate directly that p300 mediates the effect of E1A on YY1, CAT reporter plasmids under the control of either wild-type [pP5-60CAT] or mutant [pP5-60(mt2)CAT] YY1-binding sites (Shi et al. 1991) were cotransfected with p300 expression plasmids into 293 cells that constitutively express E1A (Graham et al. 1977). As shown in Figure 6, wild-type p300 increased CAT activity from pP5-60CAT but not from pP5-60(mt2)CAT, suggesting that YY1 and p300 activated transcription through YY1, in the presence of E1A [cf. lanes 2 and 3 with lanes 7 and 8]. In contrast, the mutant p300 dll0 that fails to bind E1A [Eckner et al. 1994; R. Eckner and D. Livingston, unpubl.] was unable to induce CAT activity from pP5-60CAT (Fig. 6, lanes 4,5), indicating that the activation induced by p300 requires the participation of E1A. These data strongly suggest that p300 serves as a bridging protein to connect E1A to promoter-bound YY1 for transcriptional activation.

It is possible that the mutant p300 dll0 is not only defective for binding E1A but also compromised in its ability to function as a transcriptional cofactor. To address this issue, the ability of the carboxy-terminal half of p300 (amino acids 1257–2414) and its mutant derivative containing the same internal deletion (amino acids 1679–1812) as p300 dll0 to regulate transcription was analyzed. Both forms of p300 were fused to the GAL4 DNA-binding domain (amino acids 1–147) and were found to activate GAL4–E1BCAT (data not shown). These data suggested that the carboxy-terminal half of p300 may contain the functional domain for its transcriptional coactivator function, which is not affected by the dll0 deletion mutation. Therefore, the failure of p300 dll0 to activate pP5-60CAT in 293 cells is most likely attributable to its inability to interact with E1A.

YY1 binds to a carboxy-terminal region of p300 distinct from the E1A-binding site

The YY1-interacting domain of p300 was mapped to its carboxy-terminal region [Fig. 4D,E], which also contains a binding site for E1A [Eckner et al. 1994]. To determine whether the YY1-binding site overlaps that of E1A,
Lee et al.

coomunoprecipitation experiments were performed. The carboxy-terminal half of the p300 protein \( (BglII \text{ATG, amino acids 1257-2414; Eckner et al. 1994}) \) as well as a derivative containing an internal deletion of amino acids 1737–1809 \( (BglII \text{ATG dl 30}) \) were obtained through in vitro translation. These two proteins were incubated with extracts prepared from Sf9 insect cells infected with either wild-type baculovirus or a recombinant expressing YY1. As shown in Figure 7A, both forms of the p300 protein were brought down by \( \alpha \)-YY1 antibodies (lanes 4,7) but not by preimmune antibodies (lanes 5,8). Only background signal was detected when p300 was incubated with extracts prepared from wild-type baculovirus-infected cells (lanes 3,6). In contrast, E1A was shown to interact only with the wild-type but not the mutant p300, as reported [Fig. 7A, lanes 10,13; Eckner et al. 1994], suggesting that YY1 and E1A may bind to different subregions of p300.

YY1/p300 complex is undisrupted in adenovirus-infected HeLa cells

Biochemically, two outcomes can be envisioned after E1A binds to the YY1/p300 complex: E1A may form a tripartite complex with YY1/p300, or it may disrupt the complex. To begin addressing this issue, the state of the YY1/p300 complex in adenovirus-infected HeLa cells was examined. HeLa cells were either mock infected or infected with wild-type adenovirus wt300 [Shenk et al. 1980]. Five hours postinfection, cells were harvested for preparation of extracts. The extracts were used for immunoprecipitation/Western using \( \alpha \)-YY1 antibodies for immunoprecipitation and \( \alpha \)-p300 antibodies for Western blotting analysis as described earlier. To demonstrate that E1A proteins were made in infected cells, the extracts were probed with \( \alpha \)-E1A antibodies. As shown in Figure 7B, large amount of E1A proteins were made in HeLa cells 5 hr postinfection. However, the level of the YY1/p300 complex in vivo is comparable with that in uninfected HeLa cells [Fig. 7B]. This observation, together with the fact that YY1 and E1A bind to different regions of p300 [Fig. 7A], is consistent with the notion that E1A and YY1 can bind simultaneously to the same p300 molecules.

Discussion

In this report we have described findings that uncover a molecular mechanism for the relief of YY1-mediated transcriptional repression by E1A. We began with genetic analyses of E1A domains important for relieving YY1 repression. These studies indicated the importance of p300 and suggested the existence of a YY1/p300 complex in vivo. Consequently, we searched for and identified a YY1/p300 complex in cells using multiple, independent approaches. To unequivocally demonstrate that p300 mediates functional interactions between YY1 and E1A, p300 was shown to activate CAT activity through a YY1 site in the presence of E1A. In contrast, p300 failed to activate the same CAT reporter plasmid carrying a mutated YY1 site. Furthermore, the p300 mutant unable to bind E1A also failed to activate YY1-mediated transcription. Taken together, our data showed both physical and functional associations among YY1, p300, and E1A. The functional analyses using p300 cDNA demonstrated directly the role of p300 in YY1/E1A interactions, substantiating the genetic as well as biochemical/immuno-
logical assays that implicated p300 in the relief of YY1 repression by E1A. In a separate study we have shown that removal of as few as 17 amino acids from the carboxyl terminus of YY1 abolishes its ability to respond to E1A [Lee et al. 1995].

The same YY1 mutant also failed to bind p300 in a two-hybrid assay in HeLa cells [J.S. Lee and Y. Shi, unpubl.]. Therefore, binding of YY1 to p300 correlates with the ability of E1A to modulate the transcriptional activities of YY1. This lends further support to the proposed mechanism that p300 mediates functional interactions between YY1 and E1A.

The possibility that YY1 and E1A interact directly with each other was also investigated, using cloned proteins. These studies showed that a direct interaction between these proteins, if any, appears to be rather weak under our assay conditions. Perhaps more importantly, mapping of domains involved in YY1/E1A direct interactions revealed no correlation with our functional results. When in vitro-translated, 35S-labeled YY1 was incubated with GST-13S E1A beads, only ~0.1% of the input YY1 was retained by GST-13S E1A. In contrast, the same GST-13S E1A retained ~20% of in-vitro translated RB proteins under the same assay condition. Significantly, two GST-E1A mutants lacking the amino-terminal region and CR1 of E1A (d11-28 and d11-75) captured essentially the same amount of YY1 as did wild-type GST-13S E1A [J.S. Lee and Y. Shi, unpubl.]. Functionally, deletion of the amino-terminal region or CR1 of E1A was shown to severely impair the ability of E1A to modulate the transcriptional activities of YY1. This lends further support to the proposed mechanism that p300 mediates functional interactions between YY1 and E1A.

In a separate study we have shown that removal of as few as 17 amino acids from the carboxyl terminus of YY1 abolishes its ability to respond to E1A [Lee et al. 1995]. The same YY1 mutant also failed to bind p300 in a two-hybrid assay in HeLa cells [J.S. Lee and Y. Shi, unpubl.]. Therefore, binding of YY1 to p300 correlates with the ability of E1A to modulate the transcriptional activities of YY1. The same YY1 mutant also failed to bind p300 in a two-hybrid assay in HeLa cells [J.S. Lee and Y. Shi, unpubl.]. Therefore, binding of YY1 to p300 correlates with the ability of E1A to modulate the transcriptional activities of YY1. In the absence of E1A, YY1 functions as a repressor when bound upstream of transcription initiation sites, despite the fact that YY1 also contains a potent activation domain at its amino terminus [Lee et al. 1995]. This led to the suggestion that the activation domain of YY1 is normally masked under repressing conditions. Consistent with this notion, a mutant YY1 with its activation domain replaced by a heterologous one still functions as a repressor. Interestingly, the activation domain is required for E1A to modulate the transcriptional activities of YY1 [Lee et al. 1995], although it is not involved in physical interactions with p300 or E1A. These findings suggest that interaction of E1A with YY1/p300 may cause a conformational change of YY1, resulting in unmasking of the activation domain that engages in subsequent transcriptional activation, either alone (in the case of 12S E1A) or in concert with the additional activation domain contributed by CR3 of 13S E1A.

It is worth pointing out that interpretation of the results presented in this paper is complicated by the fact that HeLa cells contain human papillomavirus E6 and E7 products (Schneider-Gadicke and Schwarz 1986). The E7 gene product shares similar functions with E1A, for example, the ability to bind pRB [Dyson et al. 1989]. Therefore, if YY1 represses transcription via multiple pathways, one of which involves pRB or its related proteins, it is conceivable that the effect of E1A could be masked by the endogenous E7 in HeLa cells. Regardless, our studies clearly indicate the importance of p300 in the relief of YY1-mediated repression by E1A.

Recently, YY1 has been shown to regulate the activity of the c-fos promoter through a mechanism involving DNA bending [Natesan and Gilman 1993]. The orientation of the YY1-binding site determines whether YY1 represses or activates the c-fos promoter. Although it is conceivable that E1A may regulate the transcriptional activities of YY1 by influencing its DNA-bending property, we were not able to detect a significant difference in the ability of YY1 to bend DNA in the presence or absence of E1A [Roberson 1990].

The biological functions of the YY1/p300 complex in the absence of E1A are currently unknown and warrant further studies. The interaction between YY1 and p300 seems important for YY1 to function as a repressor, be-
cause binding of E1A to the YY1/p300 complex affected the repressor activity of YY1. Alternatively, YY1-interacting proteins other than p300 may be responsible for the repressor activity of YY1. Initial experiments attempting to demonstrate a role for p300 in YY1-mediated repression by transfection assays in HeLa cells were inconclusive. It is possible that the assay is not sensitive enough to overcome the interference of the endogenous p300. Consistent with this possibility, it was noticed that transfection of p300 into HeLa cells barely raised the overall p300 protein level [J. S. Lee and Y. Shi, unpubl.]. It is possible that further work is required to optimize the assay conditions or other approaches may have to be implemented. For instance, a cell line with p300 null mutation, if viable, will be suitable for this purpose. Recently, in a separate study, we noticed that YY1 is transcriptionally neutral as a LexA–YY1 fusion protein in yeast [J. Kopally and Y. Shi, unpubl.]. Experiments are under way to study YY1/p300 functional interactions in yeast cells.

The cDNA encoding p300 was cloned recently, and the protein was shown to exhibit properties of a transcriptional adaptor [Eckner et al. 1994]. It was also found to share significant homology with a CREB-binding protein, CBP [Aranay et al. 1994]. CBP has been shown to be a cofactor for the CREB transcription factor [Arias et al. 1994; Kwok et al. 1994]. YY1 may be the first of many transcription factors that are partners for p300. The fact that p300 and CBP are related raises questions as to whether CBP is also involved in YY1/E1A interaction and whether YY1 affects CREB-mediated transcription via CBP. Other important issues include the specificity of p300 and CBP, which will be clarified as additional partner proteins for both proteins are uncovered. Both p300 and YY1 have been implicated in cell proliferation and differentiation [Wang et al. 1993; Shivastava and Calame 1994; Slack et al. 1995]; the finding of YY1 as a partner protein for p300 will help identify target genes that p300 may regulate through YY1. Finally, the identification of cellular complexes, such as YY1/p300 as a target of E1A, should also help us understand deregulated cell growth and tumorigenesis induced by E1A.

While this paper was under review, two papers from D. Livingston and R. Goodman’s laboratories [Aranay et al. 1995; Lundblad et al. 1995] were published demonstrating that p300/CBP mediates the interactions between CREB and E1A. Also, substantial evidence has since been obtained in our laboratory suggesting that multiple transcription factors, including CREB and members of the AP-1 family, may utilize p300 as an adaptor protein to interact with E1A [J.-S. Lee and Y. Shi, in prep.]. Together with the results presented in this paper, it appears that a theme is emerging that p300 may serve as a common cofactor that chaperones E1A to cellular DNA-binding transcription factors.

Materials and methods

Plasmids

pGAL4–TKCAT contains five GAL4-binding sites inserted upstream of the minimal adenovirus E1B promoter, which is linked to the CAT gene [gift of A. Levine, Princeton University, NJ]. pGAL4–WT1 was constructed by cloning full-length WT1 cDNA in-frame into the pG4 vector, which expresses the GAL4 (amino acids 1–147) DNA-binding domain. pGAL4–YY1, pP5-60CAT, and pP5-60mt2/CAT were described previously [Shi et al. 1991]. pcMV-125 and 135 E1A expression vectors were provided by J. Nevins [Duke University, Durham, NC]. pcMV-125 d12–36, d30–85, d120–140, Pm47/Pm124, and frameshift were gifts of M. Matthews [Cold Spring Harbor Laboratory]. pcMV135 d12–36 was constructed by using PCR methods with the following primers: 5’-CCCAAGCTTCCACCATGATTTAGCGT-GACCCTACC-3’, and 5’-CCCGGTCTTATGGCCTGGGGCGTTT-3’. 125 E1A amino-terminal point mutants, RG2, HN3, and LS20 [Wang et al. 1993] were subcloned into the pcMV-NEOBAM3 expression vector [Kageyama and Pastan 1989]. The same set of point mutants and CR1 mutant Pm47 [gift of M. Matthews] were introduced into 135 background and subcloned into the same expression vector. Wild-type p300 in the cytomegalovirus-β (CMVβ) expression vector as well as p300 plasmids for in vitro transcription/translation were described previously [Eckner et al. 1994]. The p300 d110 mutant is also in the CMVβ expression vector and contains an internal deletion removing amino acids 1679–1812. The three GST–p300 plasmids were constructed by fusing amino acids 1–596, amino acids 744–1571, and amino acids 1572–2370 in-frame with GST moiety in the pGEX–2TK vector. The C300/PV16 contains amino acids 871–2377 of p300 fused to the VP16 activation domain. The Np300/PV16 contains amino acids 1–1257 of p300 fused to the VP16 activation domain. The same regions of p300 without VP16 fusion (Cp300 and Np300) were also cloned into the CMV expression plasmid. All of the above recombinants were verified by sequence analysis.

Cells and transfections

HeLa or 293 cells were grown on 10-cm dishes in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% heat-inactivated calf serum (HeLa) or fetal calf serum (293). The cells were transfected by the calcium phosphate precipitation method as described [Shi et al. 1991]. The total amount of DNA was adjusted with the plasmid pSP72 to be identical for each transfection. Cells were harvested 48 hr after addition of the precipitate. All transfection assays were carried out with at least two independent DNA preparations and were repeated between three and eight times.

CAT assays

Whole cell extracts were prepared from the transfected cells. CAT activity was assayed as described [Shi et al. 1991] and quantitated with a Beckman LS6500 scintillation counter. Proper amounts of cell extracts were used to measure CAT activity to ensure that the assays were performed within linear range. For all the data presented, at least three independent transfections and CAT assays have been performed.

Immunoprecipitation/Western blotting assays

HeLa or 293 cells were lysed in lysis buffer [25 mM HEPES (pH 7.0), 0.25 M NaCl, 2.5 mM EDTA, 0.5 mM DTT, 10 μg/ml of leupeptin, 1 μg/ml of pepstatin A, 1 μg/ml chymostatin, 10 μg/ml of aprotonin, 2 mM phenylmethylsulfonyl fluoride, and 0.1% NP-40] for 30 min on ice. Extracts prepared from 293 (3 x 10^6) and HeLa cells (3 x 10^6) were incubated with antibodies overnight. Immune complexes were collected with protein A–Sepharose beads, washed with the lysis buffer, and eluted...
with Laemmli sample buffer. Following SDS-PAGE, proteins were transferred to nitrocellulose filters and probed with pooled α-p300 antibodies RW105 and RW128 (Eckner et al. 1994). p107 immunoblot analysis was performed by stripping the same blot and probing with α-p107 monoclonal antibody SD9 (Dyson et al. 1993), using the Immune Lite II chemiluminescence kit (BioRad).

The converse immunoprecipitation/Western blotting experiments were carried out with essentially the same procedure, except that an α-p300 monoclonal antibody RW102 (Eckner et al. 1994) was used for immunoprecipitation and affinity-purified α-YY1 polyclonal antibodies were used for Western blotting. For the immunoprecipitation/Western competition experiment, 10 μg of purified GST or GST–YY1 were incubated with the cell lysates for 1½ hours before the addition of the antibody RW102.

Analysis of YY1 and p300 interactions with GST fusion proteins

GST–p300 fusion proteins were induced and purified as described (Lee et al. 1995). HeLa cells were lysed in lysis buffer described above for 30 min on ice. Extracts prepared from HeLa cells were incubated for 4 hr with various GST–p300 fusion proteins coupled to glutathione–agarose beads (Sigma). The beads were washed with the lysis buffer, and protein complexes were eluted with Laemmli sample buffer. Following SDS-PAGE, proteins were transferred to nitrocellulose filters and probed with α-YY1 monoclonal antibodies.

For the in vitro direct interaction experiment, 5 μg of His–YY1 (purified as described previously in Shi et al. 1991) was incubated with 2 μg of GST or GST–p300 (amino acids 1572–2370) coupled to glutathione–agarose beads (Sigma). The beads were washed with the lysis buffer described above, and protein complexes were eluted with Laemmli sample buffer. Following SDS-PAGE, proteins were transferred to nitrocellulose filters and probed with affinity-purified α-YY1 polyclonal antibodies.

In vitro coimmunoprecipitation analysis

For communoprecipitation of YY1 or E1A with p300, S9 cells were lysed with NETN buffer [Kaelin et al. 1991] 36 hr after baculovirus infection. HeLa and 293 cell nuclear extracts were obtained by the Dignam procedure (Dignam et al. 1983). In vitro-translated p300 proteins were obtained by using the TNT kit (Promega). The p300 template [BgIII ATG] contains amino acids 1257–2414. The mutant di30 derivative contains essentially the same region of p300 except for an internal deletion of amino acids 1737–1809, which removes the E1A-interacting domain (Eckner et al. 1994). Immunoprecipitation reactions were performed by incubating35S-labeled, wild-type, or mutant p300 proteins with individual cell extracts as indicated in Figure 6A.

Infection of HeLa cells with adenovirus

HeLa cells were infected with wild-type 300 adenovirus at an m.o.i. of 25. The cells were harvested 6 hr after infection. Cell lysate preparations used for immunoprecipitation/western experiments were described above.

Acknowledgments

We thank P. Howley, K. Munger, P. Hinds, A. Lassar, and members of the Shi laboratory for critical reading of the manuscript and for their helpful comments. We are grateful for the gifts of plasmids from M. Mathews, and α-p107 antibody from E. Harlow and N. Dyson (Massachusetts General Hospital East, Charlestown). This work was supported by a grant to Y.S. from the National Cancer Institute, National Institutes of Health (CA8997). R.S. was supported by a postdoctoral fellowship from the Medical Research Council of Canada. Y.S. is a recipient of the American Cancer Society Junior Faculty Research Award.

The publication costs of this article were defrayed in part by payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact.

References

Arany, Z., W.R. Sellers, D.M. Livingston, and R. Eckner. 1994. E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell 77: 799–800.

Arany, Z., D. Newsome, E. Oldread, D.M. Livingston, and R. Eckner. 1995. A family of transcriptional adaptor proteins targeted by the E1A protein. Nature 374: 81–84.

Arias, J., A.S. Alberts, P. Brindle, F.X. Claret, T. Smeal, M. Karin, J. Feramisco, and M. Montminy. 1994. Activation of cAMP and mitogen responsive genes relies on a common nuclear factor. Nature 370: 226–229.

Bagchi, S., P. Raychaudhuri, and J.R. Nevins. 1990. Adenovirus E1A proteins can dissociate heteromeric complexes involving the E2F transcription factor: a novel mechanism for E1A trans-activation. Cell 62: 659–669.

Berk, A.J., and P.A. Sharp. 1978. Structure of adenovirus 2 early mRNAs. Cell 14: 695–711.

Berk, A.J., F. Lee, T. Harrison, J. Williams, and P.A. Sharp. 1979. Pre-early adenovirus 5 gene product regulates synthesis of early viral messenger RNAs. Cell 17: 935–944.

Call, K.M., T. Glaser, C.Y. Ito, A.J. Buckler, J. Pelletier, D.A. Haber, E.A. Rose, A. Kral, H. Yeger, W.H. Lewis, C. Jones, and D.E. Housman. 1990. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell 60: 509–520.

Chang, L.-S., Y. Shi, and T. Shenk. 1989. Adeno-associated virus P5 promoter contains an adenovirus E1A-inducible element and a binding site for the Major Late Transcription Factor. J. Virol. 63: 3479–3488.

Chrivita, J.C., R.P.S. Kwock, N. Lamb, M. Hagiwara, M.R. Montini, and R.H. Goodman. 1993. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 365: 855–859.

Dignam, J.D., R.M. Lebovitz, and R.G. Roeder. 1983. Accurate transcription initiation of RNA Polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11: 1475–1489.

Dyson, N. and E. Harlow. 1992. Adenovirus E1A targets key regulators for cell proliferation. In Cancer surveys (ed. A.J. Levine), pp. 161–195. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.

Dyson, N., P.M. Howley, K. Munger, and E. Harlow. 1989. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243: 934–937.

Dyson, N., M. Dembski, A. Fattaey, C. Ngwu, M. Ewen, and K. Helin. 1993. Analysis of p107-associated proteins: p107 associates with a form of E2F that differs from pRB-associated E2F. J. Virol. 67: 7641–7647.

Eckner, R., M.E. Ewen, D. Newsome, M. Gerdes, J.A. DeCaprio, J.B. Lawrence, and D.M. Livingston. 1994. Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes & Dev. 8: 869–884.

Fields, S. and O. Song. 1989. A novel genetic system to detect protein-protein interactions. Nature 340: 245–246.

Flanagan, J.R., K. Becker, D. Ennist, S.L. Gleason, P.H. Driggers, B.Z. Levi, E. Appella, and K. Ozato. 1992. Cloning of a negative transcription factor that binds to the upstream region of Moloney Murine Leukemia Virus. Mol. Cell. Biol. 12: 38–44.
Lee et al.

Graham, F.L., J. Smiley, W.C. Russell, and R. Nairn. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36: 59–72.

Harrihan, N., D. Kelley, and R.P. Perry. 1991. A transcription factor that binds to downstream elements in several promotor II promoters, is a functionally versatile zinc finger protein. Proc. Natl. Acad. Sci. 88: 9799–9803.

Harlow, E., P. Whyte, B.R. Franza Jr., and C. Schley. 1986. Association of adenovirus early-region 1A proteins with cellular polyomaviruses. Mol. Cell. Biol. 6: 1579–1589.

Horikoshi, N., K. Maguire, A. Kreli, E. Maldanado, D. Reinberg, and R. Weinmann. 1991. Direct interaction between adenovirus E1A protein and the TATA box binding transcription factor IID. Proc. Natl. Acad. Sci. 88: 5124–5128.

Jelms, T.N., J.A. Howe, J.S. Mymryk, C.M. Evelegh, N.F. Cunniff, and S.T. Bayley. 1989. Sequences in E1A proteins of human adenovirus 5 required for cell transformation, repression of a transcriptional enhancer, and induction of proliferating cell nuclear antigen. Virology 171: 120–130.

Jones, N. and T. Shenk. 1979. An adenovirus type 5 early gene function regulates expression of other early viral genes. Proc. Natl. Acad. Sci. 76: 3665–3667.

Kaelin, W.G. Jr., D.C. Pallas, J.A. DeCaprio, F.J. Kaye, and D.M. Livingston. 1991. Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the rebinoblastoma gene product. Cell 64: 521–531.

Kageyama, R. and I. Pastan. 1989. Molecular cloning and characterization of a human DNA binding factor that represses transcription. Cell 59: 815–825.

Kimelman, D., J.S. Miller, D. Porter, and B.E. Roberts. 1985. EIA region of human adenovirus and of the highly oncogenic simian adenovirus 7 are closely related. J. Virol. 53: 399–409.

Kwok, R.P.S., J.R. Lundblad, J.C. Chirivia, J.P. Richards, H.P. Bachinger, R.G. Brennan, S.G.E. Roberts, M.R. Green, and R.H. Goodman. 1994. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 370: 223–226.

Lee, J.S., R.H. See, K.M. Galvin, J. Wang, and Y. Shi. 1995. Functional interactions between YY1 and adenovirus EIA. Nucleic Acids Res. 23: 925–931.

Lee, T.-C., Y. Zhang, and R.P.S. Schwartz. 1994. Bifunctional transcriptional properties of YY1 in regulating muscle actin and c-myc gene expression during myogenesis. Oncogene 9: 1047–1052.

Lee, W.S., C.C. Kao, G.O. Bryant, X. Liu, and A.J. Berk. 1991. Adenovirus E1A activation domain binds the basic repeat in the TATA box transcription factor. Cell 67: 365–376.

Lewis, J.B. and M.B. Mathews. 1980. Control of adenovirus early gene expression: A class of immediate early products. Cell 21: 303–313.

Lillie, J.W. and M.R. Green. 1989. Transcription activation by the adenovirus EIA protein. Nature 338: 39–44.

Liu, F. and M.R. Green. 1990. A specific member of the ATF transcription factor family can mediate transcription activation by the adenovirus E1A protein. Cell 61: 1217–1224.

Lundblad, J.R., R.P.S. Kwok, M.E. Laurance, M.L. Harter, and R.H. Goodman. 1995. Adenoviral EIA-associated protein p300 as a functional homologue of the transcriptional co-activator CBP. Nature 374: 85–88.

Madden, S., D.M. Cook, J.F. Morris, A. Cashler, V. Sukhatme, and F.J. Rauscher III. 1991. Transcriptional repression mediated by the WT1 Wilms tumor gene product. Science 253: 1550–1553.

Montell, C., E.F. Fisher, M.H. Caruthers, and A.J. Berk. 1982. Resolving the functions of overlapping viral genes by site-specific mutagenesis at a mRNA splice site. Nature 295: 380–384.

Morris, G.F., and M.B. Mathews. 1991. The adenovirus E1A transforming protein activates the proliferating cell nuclear antigen promoter via an activating transcription factor site. J. Virol. 65: 6397–6406.

Natesan, S. and M.Z. Gilman. 1993. DNA bending and orientation-dependent function of YY1 in the c-fos promoter. Genes & Dev. 7: 2497–2509.

Neovis, J.R. 1981. Mechanism of activation of early viral transcription by the adenovirus E1A gene product. Cell 26: 213–230.

—. 1991. Transcriptional activation by viral regulatory proteins. Trends Biochem. Sci. 16: 435–439.

Park, K. and M. Atchison. 1991. Isolation of a candidate repressor/activator, NF-E1 (YY, 8), that binds to the immunoglobulin κ 3 enhancer and the immunoglobulin heavy-chain μE1 site. Proc. Natl. Acad. Sci. 88: 9804–9808.

Riggs, K.J., S. Saleque, K.-K. Wong, K.T. Merrell, J.-S. Lee, Y. Shi, and K. Calame. 1991. Yin-Yang-1 activates the c-myc promoter. Mol. Cell. Biol. 11: 7487–7495.

Roberson, E.D. 1990. “Sequence-directed and protein-induced DNA-bending at a locus involved in the E1A responsiveness of the adeno-associated virus P5 promoter.” Thesis, Princeton University, NJ.

Ruppert, J.M., K.W. Kinzler, A.J. Wong, S.H. Bigner, F.T. Kao, M.L. Law, H.N. Seuanez, S.J. O’Brien, and B. Vogelstein. 1988. The GLI-Kruppel family of human genes. Mol. Cell. Biol. 8: 3104–3113.

Schneider-Gadickie, A. and E. Schwarz. 1986. Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes. EMBO J. 5: 2285–2292.

Shenk, T. and J. Flint. 1991. Transcriptional and transforming activities of the adenovirus E1A proteins. Adv. Cancer Res. 57: 47–85.

—. N. Jones, C. Colby, and D. Fowkles. 1980. Functional analysis of adenovirus 5 host range deletion mutants defective for transformation of rat embryo cells. Cell 22: 3104–3113.

—. 1994. Promoter targeting by adenovirus E1A through interaction with different cellular DNA binding domains. Mol. Cell. Biol. 14: 3104–3113.

—. 1993. Identification of specific adenovirus E1A amino-terminal residues critical to the binding of cellular proteins and to the control of cell growth. J. Virol. 67: 476–488.

Shrikavastava, A. and K. Calame. 1994. An analysis of genes regulated by the multi-functional transcriptional regulator Yin-Yang-1. Nucleic Acids Res. 22: 5151–5155.

Slack, R.S., J. Craig, S. Costa, and M.W. McBurney. 1995. Adenovirus 5 E1A induced differentiation of P19 embryonal carcinoma cells requires binding to p300. Oncogene 10: 19–25.

Wilson, A., K. LaMarco, M.G. Peterson, and W. Herr. 1993. The VP16 accessory protein HCF is a family of polypeptides processed from a large precursor protein. Cell 74: 115–125.

Yee, S.P. and P.E. Branton. 1985. Detection of cellular proteins associated with human adenovirus type 5 early region 1A polypeptides. Virology 147: 142–153.
Relief of YY1 transcriptional repression by adenovirus E1A is mediated by E1A-associated protein p300.

J S Lee, K M Galvin, R H See, et al.

*Genes Dev.* 1995, 9:
Access the most recent version at doi:10.1101/gad.9.10.1188

References

This article cites 53 articles, 19 of which can be accessed free at: http://genesdev.cshlp.org/content/9/10/1188.full.html#ref-list-1

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here.]